Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, AR; Shah, NN; Jurczak, W; Cheah, CY; Pagel, JM; Woyach, JA; Fakhri, B; Eyre, TA; Lamanna, N; Patel, MR; Alencar, A; Lech-Maranda, E; Wierda, WG; Coombs, CC; Gerson, JN; Ghia, P; Le Gouill, S; Lewis, DJ; Sundaram, S; Cohen, JB; Flinn, IW; Tam, CS; Barve, MA; Kuss, B; Taylor, J; Abdel-Wahab, O; Schuster, SJ; Palomba, ML; Lewis, KL; Roeker, LE; Davids, MS; Tan, XN; Fenske, TS; Wallin, J; Tsai, DE; Ku, NC; Zhu, E; Chen, J; Yin, M; Nair, B; Ebata, K; Marella, N; Brown, JR; Wang, M
(2021), Lancet, 892-901
The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma
Gao, C; McCormack, CJ; van der Weyden, C; Twigger, R; Buelens, O; Lade, S; Khoo, C; Campbell, BA; Goh, M; McKelvie, P; Prince, HM
(2021), J. Am. Acad. Dermatol., 185-187
Review of Venetoclax in CLL, AML and Multiple Myeloma
Lasica, M; Anderson, MA
(2021), J. Pers. Med.
DOI: 10.3390/jpm11060463
Clinical ethics resources from the Royal Australasian College of Physicians
Isaacs, D; Szer, J
(2021), J. Paediatr. Child Health, 751-751
DOI: 10.1111/jpc.15444
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Wang, M; Ramchandren, R; Chen, R; Karlin, L; Chong, G; Jurczak, W; Wu, KL; Bishton, M; Collins, GP; Eliadis, P; Peyrade, F; Lee, Y; Eckert, K; Neuenburg, JK; Tam, CS
(2021), J. Hematol. Oncol.
Teriparatide Treatment for Medication-Related Osteonecrosis of the Jaw: Is This an Effective Option? Reply
Sim, IW; Borromeo, GL; Seymour, JF; Ebeling, PR
(2021), J. Clin. Oncol., 173
DOI: 10.1200/JCO.20.02906
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Bahlis, NJ; Baz, R; Harrison, SJ; Quach, H; Ho, SJ; Vangsted, AJ; Plesner, T; Moreau, P; Gibbs, SD; Coppola, S; Yang, XQ; Al Masud, A; Ross, JA; Bueno, O; Kaufman, JL
(2021), J. Clin. Oncol., 3602
DOI: 10.1200/JCO.21.00443
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, JC; Hillmen, P; Ghia, P; Kater, AP; Chanan-Khan, A; Furman, RR; O'Brien, S; Yenerel, MN; Illes, A; Kay, N; Garcia-Marco, JA; Mato, A; Pinilla-Ibarz, J; Seymour, JF; Lepretre, S; Stilgenbauer, S; Robak, T; Rothbaum, W; Izumi, R; Hamdy, A; Patel, P; Higgins, K; Sohoni, S; Jurczak, W
(2021), J. Clin. Oncol., 3441
DOI: 10.1200/JCO.21.01210
We must grow the Australian Bone Marrow Donor Registry
Cliff, ERS; Szer, J
(2021), Intern. Med. J., 1771-1772
DOI: 10.1111/imj.15570
The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients
Lapirow, D; La Gerche, A; Toro, C; Masango, E; Costello, B; Porello, E; Ludlow, L; Marshall, G; Trahair, T; Mateos, M; Lewin, J; Byrne, J; Boutros, R; Manudhane, R; Heath, J; Ayer, J; Gabriel, M; Walwyn, T; Saundankar, J; Forsey, J; Le, H; Mason, K; Celermajer, D; Downie, P; Walker, R; Holland, L; Martin, M; McLeman, L; Diamond, Y; Marcocci, M; Donath, S; Cheung, M; Elliott, DA; Conyers, R
(2021), Intern. Med. J., 229-234
DOI: 10.1111/imj.14719
Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron-deficiency anaemia: a Phase II single-arm study
Pasricha, SR; Gilbertson, M; Indran, T; Bennett, A; van Dam, M; Coughlin, E; Dev, A; Chunilal, S; Opat, S
(2021), Intern. Med. J., 1304-1311
DOI: 10.1111/imj.15195
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
McCaughan, G; Di Ciaccio, P; Ananda-Rajah, M; Gilroy, N; MacIntyre, R; Teh, B; Weinkove, R; Curnow, J; Szer, J; Enjeti, AK; Ross, DM; Mulligan, S; Trotman, J; Dickinson, M; Quach, H; Choi, P; Polizzotto, MN; Tam, CS; Ho, PJ; Ku, M; Gregory, G; Gangatharan, S; Hapgood, G; Cochrane, T; Cheah, C; Gibbs, S; Wei, A; Johnston, A; Greenwood, M; Prince, HM; Latimer, M; Berkahn, L; Wight, J; Armytage, T; Hamad, N
(2021), Intern. Med. J., 763-768
DOI: 10.1111/imj.15247
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Douglas, AP; Smibert, OC; Bajel, A; Halliday, CL; Lavee, O; McMullan, B; Yong, MK; Hal, SJ; Chen, SCA
(2021), Intern. Med. J., 143-176
DOI: 10.1111/imj.15591
Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021
Fernando, SS; Paige, EK; Dendle, C; Weinkove, R; Kong, DCM; Omond, P; Routledge, DJ; Szer, J; Blyth, CC
(2021), Intern. Med. J., 220-233
DOI: 10.1111/imj.15593
Clinical Ethics resources from the Royal Australasian College of Physicians
Isaacs, D; Szer, J
(2021), Intern. Med. J., 315-315
DOI: 10.1111/imj.15264
Autologous stem cell transplantation in elderly multiple myeloma patients aged >= 65 years: a two-centre Australian experience
Er, J; Routledge, D; Hempton, J; Wood, C; Joyce, T; Harrison, S; Campbell, P
(2021), Intern. Med. J., 280-283
DOI: 10.1111/imj.15182
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
Cochrane, T; Campbell, BA; Gangatharan, SA; Latimer, M; Khor, R; Christie, DRH; Gilbertson, M; Ratnasingam, S; Palfreyman, E; Lee, HP; Trotman, J; Hertzberg, M; Dickinson, M
(2021), Intern. Med. J., 2119-2128
DOI: 10.1111/imj.15503
Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development
Monagle, P; Ng, AP; Linden, M; Ignjatovic, V; Farley, A; Taoudi, S; Pasricha, SR; Torresi, J
(2021), Immunol. Cell Biol., 1006-1010
DOI: 10.1111/imcb.12505
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Al-Sawaf, O; Seymour, JF; Kater, AP; Fischer, K
(2021), Hematol. Oncol. Clin. North Am., 775-791
Upfront therapy: the case for continuous treatment
Tam, CS
(2021), Hematol.-Am. Soc. Hematol. Educ. Program, 55-58
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents
Molica, S; Seymour, JF; Polliack, A
(2021), Hematol. Oncol., 595-604
DOI: 10.1002/hon.2929
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Tam, CS; Robak, T; Ghia, P; Kahl, BS; Walker, P; Janowski, W; Simpson, D; Shadman, M; Ganly, PS; Laurenti, L; Opat, S; Tani, M; Ciepluch, H; Verner, E; Simkovi, M; Osterborg, A; Trneny, M; Tedeschi, A; Paik, JC; Kuwahara, SB; Feng, SB; Ramakrishnan, V; Cohen, A; Huang, J; Hillmen, P; Brown, JR
(2021), Haematologica, 2354-2363
Myeloma natural killer cells are exhausted and have impaired regulation of activation
D'Souza, C; Keam, SP; Yeang, HXA; Neeson, M; Richardson, K; Hsu, AK; Canfield, R; Bezman, N; Robbins, M; Quach, H; Ritchie, DS; Harrison, SJ; Trapani, JA; Prince, HM; Beavis, PA; Darcy, PK; Neeson, PJ
(2021), Haematologica, 2522-2526
Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
Brodsky, RA; de Latour, RP; Rottinghaus, ST; Roth, A; Risitano, AM; Weitz, IC; Hillmen, P; Maciejewski, JP; Szer, J; Lee, JW; Kulasekararaj, AG; Volles, L; Damokosh, AI; Ortiz, S; Shafner, L; Liu, P; Hillc, A; Schrezenmeier, H
(2021), Haematologica, 230-237
Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing
Tian, LY; Jabbari, JS; Thijssen, R; Gouil, Q; Amarasinghe, SL; Voogd, O; Kariyawasam, H; Du, MRM; Schuster, J; Wang, CQ; Su, SA; Dong, XY; Law, CW; Lucattini, A; Prawer, YDJ; Collar-Fernandez, C; Chung, JD; Naim, T; Chan, A; Ly, CH; Lynch, GS; Ryall, JG; Anttila, CJA; Peng, HK; Anderson, MA; Flensburg, C; Majewski, I; Roberts, AW; Huang, DCS; Clark, MB; Ritchie, ME
(2021), Genome Biol.
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
Dreyling, M; Tam, CS; Wang, M; Smith, SD; Ladetto, M; Huang, HQ; Novotny, W; Co, M; Romano, A; Holmgren, E; Huang, JE; Le Gouill, S
(2021), Future Oncol., 255-262
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka, AK; Weisel, K; van de Donk, NWCJ; Routledge, D; Otero, PR; Song, KV; Quach, H; Callander, N; Minnema, MC; Trudel, S; Jackson, NA; Ahlers, CM; Im, E; Cheng, S; Smith, L; Hareth, N; Ferron-Brady, G; Brouch, M; de Oca, RM; Paul, S; Holkova, B; Gupta, I; Kremer, BE; Richardson, P
(2021), Future Oncol., 1987-2003
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C; Prince, HM; Neeson, PJ
(2021), Front. Immunol.
Paving the way to precision medicine in multiple myeloma
Inam, S; Ross, JA; Touzeau, C; Moreau, P; Kumar, SK; Harrison, SJ
(2021), Expert Rev. Hematol., 323-327